Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Mitomycin C (MMC) and Interferon α2B (IFNα2B) in the management of ocular surface squamous neoplasia (OSSN): when does it help?

Search Title by author or title

Session Details

Session Title: Cornea: Medical

Session Date/Time: Tuesday 10/10/2017 | 08:00-10:30

Paper Time: 08:54

Venue: Room 3.6

First Author: : R.Rajagopal INDIA

Co Author(s): :    K. Popat   G. Iyer   B. Srinivasan              

Abstract Details


Topical MMC and IFNα2B have rarely been used as a primary modality of treatment in OSSN either for chemo reduction before surgery (lesions > 6 clock hrs / multifocal) or chemotherapy (localised/corneal lesions). We reviewed indications and outcome of the same.


Department of Cornea and Refractive Surgery, Medical Research Foundation, Chennai, India


Case records of 13 patients primarily treated with either 0.04% MMC (9), IFNα2B (1 million IU/ml) (2) or both sequentially (2) were reviewed : Commonest morphology was papillomatous (7).


Papillomatous lesions responded the best (57.14%).Chemoreduction was initiated in 5 eyes (4 MMC/1 IFNα2B-epithelial toxicity)- lesions completely resolved in 3 (papillomatous) (1 MMC,1 IFNα2B, 1 MMC followed by IFNα2B).1 had partial response followed by surgery (corneal),1 lost to follow up(LTFU). Chemotherapy was initiated in 8 (7 MMC, 1 IFNα2B - patient opted). Complete resolution occurred in 2 (IFNα2B 1, MMC followed by IFNα2B 1) with no recurrence over 24 months. Mean time to resolution was 3 months. 3 eyes showed partial response and underwent surgical excision- 2 had no response (operated),1was LTFU.No toxicity was observed.


Primary chemotherapy should be considered in papillomatous, multifocal and/or diffuse lesions. Toxicity is seldom seen. MMC is preferred in papillomatous lesions and is cost effective, while Interferon is preferred in pre-existing epithelial changes.

Financial Disclosure:


Back to previous